nasdaq is overdue and an explanation is reqd, page-6

I must admit, I have been scratching my head about this issue for a while now. A couple on months ago I came to the conclusion (my opinion only) that the company has put the SEC process on the slow track for strategic reasons.

MR will naturally make no comment on this (quite rightly), but my suspicion is they have been waiting for a more advantageous opportunity to list on the Nasdaq. They would not like to see it list and fall flat, setting up a negative perspective for the stock in the US. You only get one chance to make a first impression.

I'm pretty sure the Dendreon SP collapse had a major impact on this, and ongoing macro-economic uncertainty is a factor too. Now that DNDN has signalled improvement and the market is once again viewing it more favourably, who knows.

I personally think there are 2 significant events that need to be watched carefully and could be the triggers;

1. Phase IIb trial results - expected mid year.

2. Oncotheyreon (ONTY) Phase III results for Stimuvax - also expected mid year. (MR has previously made a point of emphasising the influence of this event).

So all things considered, I reckon the listing is more likely to happen in the 3rd quarter of 2012, but as always it's merely one clowns opinion here. I may have put 2 + 2 together and got "elephant".

Cheers.